Literature DB >> 21507163

Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.

H Moore1, K Romeril.   

Abstract

Multiple myeloma rarely presents with a fever of unknown origin and diagnosis may be delayed. We describe a case of myeloma presenting in this way with raised serum-free light chains and TP53 deletion on cytogenetics. The patient developed thrombotic thrombocytopenia purpura (TTP) following bortezomib therapy but recovered spontaneously and was successfully re-challenged. We believe this is only the second case to describe this phenomenon post-bortezomib and the first to rechallenge the patient successfully without further recurrence of TTP. Possible mechanisms for this successful rechallenge are discussed.
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21507163     DOI: 10.1111/j.1445-5994.2011.02458.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  12 in total

1.  Thrombotic thrombocytopenic purpura as initial and major presentation of multiple myeloma.

Authors:  Xiang Xiao; Hai-ying Zhong; Guang-sen Zhang; Ming-yang Deng
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

2.  Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma.

Authors:  Christopher D Hamad; Zachary C Hoelscher; Amanda Tchakarov; Jaya Kala
Journal:  CEN Case Rep       Date:  2022-01-07

Review 3.  Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

Authors:  Rimda Wanchoo; Ala Abudayyeh; Mona Doshi; Amaka Edeani; Ilya G Glezerman; Divya Monga; Mitchell Rosner; Kenar D Jhaveri
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-21       Impact factor: 8.237

4.  Bortezomib-induced thrombotic thrombocytopaenic purpura.

Authors:  Neha Mehta; Ashish Saxena; Ruben Niesvizky
Journal:  BMJ Case Rep       Date:  2012-08-01

5.  Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.

Authors:  Liliane Hobeika; Sally E Self; Juan Carlos Q Velez
Journal:  BMC Nephrol       Date:  2014-09-30       Impact factor: 2.388

6.  Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib.

Authors:  Suheil Albert Atallah-Yunes; Myat Han Soe
Journal:  Case Rep Hematol       Date:  2018-07-03

7.  Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.

Authors:  Clarissa A Cassol; Michael P A Williams; Tiffany N Caza; Sophia Rodriguez
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

Review 8.  Thrombotic microangiopathy associated with proteasome inhibitors.

Authors:  Ahad Lodhi; Abhishek Kumar; Muhammad U Saqlain; Manish Suneja
Journal:  Clin Kidney J       Date:  2015-07-16

9.  Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma.

Authors:  Jan Van Keer; Michel Delforge; Daan Dierickx; Kathelijne Peerlinck; Evelyne Lerut; Ben Sprangers
Journal:  Case Rep Hematol       Date:  2016-05-16

Review 10.  The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer.

Authors:  Chanukya K Colonne; Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Healthcare (Basel)       Date:  2022-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.